Posted on October 18, 2017 by Sitemaster
Apparently a group of Japanese researchers determined a while ago that we need to know whether abiraterone acetate (Zytiga) or enzalutamide (Xtandi) is the better drug for first-line treatment of chemotherapy-naive patients with castration-resistant prostate cancer (CRPC) — whether it is metastatic or non-metastatic in type. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, enzalutamide, head-to head, trial | Leave a comment »
Posted on October 16, 2017 by Sitemaster
On and off over the past few years your sitemaster has raised the question of whether there is any real clinical benefit to maintaining men on standard androgen deprivation therapy (ADT) once they become castrate resistant and are switched to treatment with newer drugs like abiraterone acetate (Zytiga) or enzalutamide (Xtandi). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen, castration-resistant, deprivation, mCRPC, metastatic, SPARE, trial | Leave a comment »
Posted on October 3, 2017 by Sitemaster
One of the clinical questions that is now beginning to be asked really seriously is this one: “Just how aggressively should we treat a man with high-risk progressive prostate cancer after first-line therapy?” … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", abiraterone, androgen, annihilation, apalutimide, Degarelix, hormone-sensitive, nmHSPC, non-metatstaic | 8 Comments »
Posted on September 11, 2017 by Sitemaster
A presentation at the ongoing annual meeting of the European Society of Medical Oncology (ESMO), in Madrid, Spain, has offered us data comparing abiraterone acetate + prednisone + ADT to docetaxel + ADT in the treatment of men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen deprivation, docetaxel, hormone-sensitive, metastatic, mHSPC | 4 Comments »
Posted on July 20, 2017 by Sitemaster
In January and May this year we had noted that a company called Churchill Pharmaceuticals has been developing a different formulation of ultramicron-sized, oral abiraterone acetate (to be called Yonsa™). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, Churchill, formulation, submicron, Yonsa | 2 Comments »
Posted on June 5, 2017 by Sitemaster
So one of the benefits of being at the annual ASCO meeting is that you get to talk to lots of medical oncologists who specialize in treating prostate cancer — if you are patient and polite. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, hromone-sensitive, latitude, metastatic, STAMPEDE | 6 Comments »
Posted on June 5, 2017 by Sitemaster
The data previously reported from the STAMPEDE trial and the LATITUDE trial over the past couple of days were from men newly diagnosed with high-risk and/or metastatic forms of prostate cancer, but … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", abiraterone, ADT, metastatic, Treatment | 6 Comments »
Posted on June 3, 2017 by Sitemaster
The abstracts of the LATITUDE trial and the comparable arm of the STAMPEDE trial, in which patients with newly diagnosed, metastatic prostate cancer were randomized to either ADT or ADT + abiraterone acetate + prednisone were both released this morning. Both trials have shown major benefits to the early addition of abiraterone acetate to standard care. We shall be providing more details in separate reports to come later today.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: abiraterone, metastatic, survival | Leave a comment »
Posted on May 18, 2017 by Sitemaster
Near the end of last month we had told you that data from the LATITUDE trial and from Arm G of the STAMPEDE trial would be presented at the ASCO annual meeting in Chicago this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, outcome, trial, Zytiga | Leave a comment »
Posted on April 28, 2017 by Sitemaster
We have just heard from the STAMPEDE trial group in the UK that they will be presenting overall survival data from the “abiraterone comparison” arm of the STAMPEDE trial at the upcoming ASCO meeting this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, enzalutamide, STAMPEDE | 2 Comments »
Posted on April 27, 2017 by Sitemaster
According to an e-mail your sitemaster has just received from ASCO, we will be getting the initial results from the LATITUDE trial at the upcoming ASCO meeting in June this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, latitude, outcome, trial | 5 Comments »
Posted on December 20, 2016 by Sitemaster
According to a recent media release, there was no significant benefit for the investigational combination of enzalutamide (Xtandi) + abiraterone acetate (Zytiga) + prednisone in treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (cnmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, chemotherapy-naïve, combination, CRPC, enzalutamide, metastatic | 1 Comment »
Posted on October 7, 2016 by Sitemaster
We understand from the manufacturers that the so-called ERA-223 trial — a randomized, double-blind, multi-center, Phase III trial of radium-223 acetate (Xofigo) + abiraterone acetate (Zytiga) + prednisone compared to a placebo + abiraterone acetate + prednisone — is now fully enrolled. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, mCRPC, metastatic, radium-223, trial | 1 Comment »
Posted on October 5, 2016 by Sitemaster
Does adding dutasteride (Avodart) to abiraterone acetate (Zytiga) make any difference in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC)? There is no clear answer to this question from a small, Phase II, pilot study, the results of which have just been published in Clinical Cancer Research. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: abiraterone, castration-resistant, CRPC, dutasteride, metsatatic | 6 Comments »
Posted on March 21, 2016 by Sitemaster
New guidance in England has expanded coverage of treatment with abiraterone acetate (Zytiga) + prednisone for men with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, coverage, NICE, Zytiga | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 